Olema Pharmaceuticals Analyst Ratings
Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Olema Pharmaceuticals Analyst Ratings
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $30 Price Target
Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials
Buy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic Collaborations
Olema Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination
Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies
Olema Pharmaceuticals Analyst Ratings
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
Olema Pharmaceuticals Analyst Ratings
Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), 2seventy Bio (TSVT) and Marinus (MRNS)
Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration
Promising Future for Olema Pharmaceuticals With Palazestrant in Breast Cancer Treatment: A Buy Rating
Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge
Olema Pharmaceuticals Analyst Ratings
Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment
Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity